MCID: SCH015
MIFTS: 69

Schizophrenia

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia

MalaCards integrated aliases for Schizophrenia:

Name: Schizophrenia 57 38 12 76 25 75 37 29 13 55 6 43 44 15 40 73
Schizophrenia, Susceptibility to 57 13 6
Schizophrenia with or Without an Affective Disorder 57 75
Schizophrenia 12 57 73
Sczd 57 75
Dementia Praecox 25
Schizophrenia 1 73
Schizophrenia-1 12

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity
onset often in late adolescence
symptoms must occur for 6 months including 1 month of characteristic symptoms (e.g. delusions) to make diagnosis
multiple gene loci involved in causation of schizophrenia


HPO:

32
schizophrenia:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 181500
Disease Ontology 12 DOID:5419
ICD9CM 35 295.8 295.80
MeSH 44 D012559
KEGG 37 H01649
ICD10 33 F20 F20.9

Summaries for Schizophrenia

MedlinePlus : 43 Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves. Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms: Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. "Negative" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn. Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention. No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role. There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training. NIH: National Institute of Mental Health

MalaCards based summary : Schizophrenia, also known as schizophrenia, susceptibility to, is related to paranoid schizophrenia and schizoaffective disorder, and has symptoms including sleep disturbances, photophobia and personality changes. An important gene associated with Schizophrenia is RTN4R (Reticulon 4 Receptor), and among its related pathways/superpathways are Dopaminergic synapse and Neuroactive ligand-receptor interaction. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are hallucinations and delusions

Disease Ontology : 12 A psychotic disorder that is characterized by a disintegration of thought processes and of emotional responsiveness.

Genetics Home Reference : 25 Schizophrenia is a brain disorder classified as a psychosis, which means that it affects a person's thinking, sense of self, and perceptions. The disorder typically becomes evident during late adolescence or early adulthood.

OMIM : 57 Schizophrenia is a psychosis, a disorder of thought and sense of self. Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. There is no characteristic pathology, such as neurofibrillary tangles in Alzheimer disease (104300). Schizophrenia is a common disorder with a lifetime prevalence of approximately 1%. It is highly heritable but the genetics are complex. This may not be a single entity. Schizophrenia and bipolar disorder (see 125480) are generally considered to be separate entities, but patients who exhibit multiple symptoms of both disorders are often given the hybrid diagnosis schizoaffective disorder (Blacker and Tsuang, 1992). (181500)

UniProtKB/Swiss-Prot : 75 Schizophrenia: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

Wikipedia : 76 Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to understand... more...

Related Diseases for Schizophrenia

Diseases in the Schizophrenia family:

Schizophrenia 1 Schizophrenia 3
Schizophrenia 4 Schizophrenia 6
Schizophrenia 5 Schizophrenia 7
Schizophrenia 8 Schizophrenia 2
Schizophrenia 9 Schizophrenia 10
Schizophrenia 11 Schizophrenia 12
Schizophrenia 14 Schizophrenia 13
Schizophrenia 15 Schizophrenia 16
Schizophrenia 18 Schizophrenia 19
Early-Onset Schizophrenia

Diseases related to Schizophrenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 438)
# Related Disease Score Top Affiliating Genes
1 paranoid schizophrenia 36.0 COMT HTR2A MIAT
2 schizoaffective disorder 35.9 COMT DAOA DISC1 DISC2 DRD3 HTR2A
3 early-onset schizophrenia 35.5 COMT DRD3 HTR2A
4 schizophrenia 5 35.3 DRD3 HTR2A
5 psychotic disorder 34.9 AKT1 CHI3L1 COMT DAOA DISC1 DRD3
6 bipolar disorder 34.2 COMT DAOA DAOA-AS1 DISC1 DISC2 DRD3
7 mood disorder 33.4 COMT DAOA DISC1 DISC2 DRD3 HTR2A
8 major depressive disorder 33.3 COMT DISC1 DISC2 DRD3 HTR2A MTHFR
9 tardive dyskinesia 33.1 COMT DRD3 HTR2A
10 autism 33.0 COMT DISC1 DRD3 HTR2A SYN2
11 personality disorder 32.8 COMT DRD3 HTR2A
12 substance abuse 32.4 COMT DRD3 MIAT
13 disease of mental health 32.4 COMT DISC1 DRD3 HTR2A
14 obsessive-compulsive disorder 32.3 COMT DRD3 HTR2A
15 panic disorder 31.7 COMT DAOA-AS1 HTR2A
16 anorexia nervosa 31.4 COMT HTR2A MC4R
17 pathological gambling 31.2 DRD3 HTR2A
18 parkinson disease, late-onset 31.0 AKT1 COMT DRD3 HTR2A
19 childhood-onset schizophrenia 12.4
20 schizophrenia 4 12.3
21 schizophrenia 2 12.3
22 schizophrenia 1 12.3
23 schizophrenia 3 12.2
24 schizophrenia 15 12.2
25 schizophrenia 9 12.2
26 schizophrenia 18 12.2
27 schizophrenia 12 12.2
28 schizophrenia 19 12.2
29 schizophrenia 6 12.1
30 schizophrenia 8 12.1
31 schizophrenia 14 12.1
32 schizophrenia 13 12.1
33 schizophrenia 7 12.1
34 schizophrenia 10 12.1
35 schizophrenia 11 12.1
36 schizophrenia 16 12.1
37 chromosome 2p16.3 deletion syndrome 11.8
38 migraine with or without aura 1 11.6 COMT DRD3 HTR2A MTHFR
39 schizophreniform disorder 11.4
40 polysubstance abuse 11.3 COMT DRD3
41 neuroleptic malignant syndrome 11.1
42 systemic lupus erythematosus 11.1
43 syngap1-related non-syndromic intellectual disability 10.8
44 darier-white disease 10.8
45 dopamine beta-hydroxylase deficiency, congenital 10.8
46 hyperprolinemia, type i 10.8
47 chromosome 15q13.3 deletion syndrome 10.8
48 chromosome 1q21.1 deletion syndrome, 1.35-mb 10.8
49 childhood-onset cerebral x-linked adrenoleukodystrophy 10.8
50 social emotional agnosia 10.8

Comorbidity relations with Schizophrenia via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Heart Disease Hypothyroidism
Iron Deficiency Anemia Major Depressive Disorder
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Tardive Dyskinesia

Graphical network of the top 20 diseases related to Schizophrenia:



Diseases related to Schizophrenia

Symptoms & Phenotypes for Schizophrenia

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
hallucinations
schizophrenia
delusions
social and occupational deterioration
disorganized speech
more
Laboratory Abnormalities:
abnormal eeg in 25% hospitalized patients


Clinical features from OMIM:

181500

Human phenotypes related to Schizophrenia:

32
# Description HPO Frequency HPO Source Accession
1 hallucinations 32 HP:0000738
2 delusions 32 HP:0000746
3 eeg abnormality 32 very rare (1%) HP:0002353
4 social and occupational deterioration 32 HP:0007086
5 schizophrenia 32 HP:0100753

UMLS symptoms related to Schizophrenia:


sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

Drugs & Therapeutics for Schizophrenia

Drugs for Schizophrenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 700)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
3
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585
4
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
5
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 146939-27-7 60854
6
Curcumin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 458-37-7 969516
7
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
8
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5786-21-0 2818
9
Etomidate Approved Phase 4 33125-97-2 36339 667484
10
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
11
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
12
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
13
Reboxetine Approved, Investigational Phase 4,Phase 3,Phase 1 98769-81-4, 71620-89-8 123628 65856
14
Sulpiride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15676-16-1 5355
15
Metformin Approved Phase 4,Phase 3,Not Applicable 657-24-9 14219 4091
16
Huperzine A Approved, Investigational Phase 4,Phase 2 102518-79-6
17
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-86-8 3559
18
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 112111-43-0
19
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 68693-11-8 4236
20
Guanfacine Approved, Investigational Phase 4,Phase 2,Not Applicable 29110-47-2 3519
21
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10118-90-8 5281021
22
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-53-3 2726
23
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
24
Linagliptin Approved Phase 4,Phase 1 668270-12-0 10096344
25 Benperidol Approved, Investigational Phase 4,Phase 3,Phase 2 2062-84-2
26 bromperidol Approved, Investigational Phase 4,Phase 3 10457-90-6 2448
27
Fluphenazine Approved Phase 4,Phase 3,Phase 2 69-23-8 3372
28
Fluspirilene Approved, Investigational Phase 4,Phase 3 1841-19-6 3396
29 Perazine Approved, Investigational Phase 4,Phase 3 84-97-9
30
Perphenazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-39-9 4748
31
Pimozide Approved Phase 4,Phase 3,Phase 2 2062-78-4 16362
32
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
33
Methyltestosterone Approved Phase 4 58-18-4 6010
34
Testosterone Approved, Investigational Phase 4 58-22-0 6013
35
Testosterone enanthate Approved Phase 4 315-37-7 9416
36
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
37
Ethanol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 64-17-5 702
38
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
39
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 75614-87-8, 51-45-6 774
40
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99-66-1 3121
41
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-56-6 439302 53477758
42
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 19982-08-2 4054
43
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Not Applicable 54739-18-3 3404 5324346
44
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
45
Famotidine Approved Phase 4,Phase 2,Phase 3 76824-35-6 3325
46
Galantamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 357-70-0 9651
47
Trifluoperazine Approved, Investigational Phase 4,Phase 3 117-89-5 5566
48
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
49
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 50-36-2 5760 446220
50
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 61869-08-7 43815

Interventional clinical trials:

(show top 50) (show all 3160)
# Name Status NCT ID Phase Drugs
1 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
2 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
3 Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients Unknown status NCT02298985 Phase 4 Curcumin;placebo
4 Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients Unknown status NCT01399450 Phase 4 paliperidone
5 A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia Unknown status NCT01490567 Phase 4 Donepezil;placebo
6 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
7 Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia Unknown status NCT02282085 Phase 4 Aripiprazole Once-Monthly;Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
8 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4 Moxonidine;Placebo;Moxonidine;Placebo
9 Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia Unknown status NCT00186771 Phase 4
10 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
11 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
12 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
13 Diabetes Prevention Program in Schizophrenia [DPPS] Unknown status NCT00182494 Phase 4
14 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
15 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
16 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
17 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
18 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
19 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
20 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
21 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
22 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
23 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
24 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
25 Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch Unknown status NCT02697045 Phase 4 Aripiprazole 400mg LAI
26 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
27 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
28 Linagliptin and Mesenchymal Stem Cells: A Pilot Study Unknown status NCT02442817 Phase 4 Linagliptin
29 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
30 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
31 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
32 A Pharmacokinetic Study of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
33 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
34 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Unknown status NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
35 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
36 The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine Unknown status NCT01654640 Phase 4 Metformin;Placebo (for metformin)
37 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
38 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
39 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
40 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4 Asenapine
41 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
42 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
43 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
44 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
45 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
46 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
47 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Unknown status NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
48 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
49 The Effects of Nicotine on Cognition in Schizophrenia Completed NCT00383747 Phase 4 transdermal nicotine patch;Transdermal Nicotine Patch
50 Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders Completed NCT01081418 Phase 4

Search NIH Clinical Center for Schizophrenia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: schizophrenia

Genetic Tests for Schizophrenia

Genetic tests related to Schizophrenia:

# Genetic test Affiliating Genes
1 Schizophrenia 29 AKT1 APOL2 APOL4 CHI3L1 COMT DAO DAOA DISC1 DISC2 DRD3 DTNBP1 HTR2A MTHFR RTN4R SYN2

Anatomical Context for Schizophrenia

MalaCards organs/tissues related to Schizophrenia:

41
Brain, Cortex, Testes, Prefrontal Cortex, Eye, Cingulate Cortex, Temporal Lobe

Publications for Schizophrenia

Articles related to Schizophrenia:

(show top 50) (show all 11325)
# Title Authors Year
1
A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder. ( 29619682 )
2018
2
Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach. ( 29440730 )
2018
3
A systematic review of health economic models and utility estimation methods in schizophrenia. ( 29347854 )
2018
4
Schizophrenia heterogeneity revisited: Clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups. ( 29156414 )
2018
5
Verbal learning and hippocampal dysfunction in schizophrenia: A meta-analysis. ( 29223768 )
2018
6
Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States. ( 29606075 )
2018
7
Patient Satisfaction and Quality of Life in People with Schizophrenia-Spectrum Disorders in a Rural Area. ( 28756572 )
2018
8
Correction: Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. ( 29451914 )
2018
9
Predictors of negative symptoms in the chronic phase of schizophrenia: A cross-sectional study. ( 28965809 )
2018
10
Clinical implication of smoking among patients with schizophrenia at a Tertiary Institution in South East Nigeria. ( 29977263 )
2018
11
DNA methylation landscape of the genes regulating D-serine and D-aspartate metabolism in post-mortem brain from controls and subjects with schizophrenia. ( 29976992 )
2018
12
Attenuated resting-state functional connectivity in patients with childhood- and adult-onset schizophrenia. ( 29310911 )
2018
13
The effects of psychological help on assertive behaviors in family members of schizophrenia patients. ( 29975367 )
2018
14
The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. ( 29125018 )
2018
15
The reasons for use of cannabinoids and stimulants in patients with schizophrenia. ( 29975366 )
2018
16
Pharmacological treatment for schizoaffective disorder : A comparison with schizophrenia and bipolar disorder. ( 29564469 )
2018
17
The Cognitive Screening Scale for Schizophrenia (CSSS) - Part 2: Validity of the Scale. ( 29975364 )
2018
18
Objective investigation of activity preference in schizophrenia: A pilot study. ( 29980136 )
2018
19
Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. ( 28849318 )
2018
20
Priming production: Neural evidence for enhanced automatic semantic activity preceding language production in schizophrenia. ( 29387525 )
2018
21
Associations between the DBH gene, plasma dopamine I^-hydroxylase activity and cognitive measures in Han Chinese patients with schizophrenia. ( 28647493 )
2018
22
Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis. ( 29450447 )
2018
23
Abnormal regional homogeneity as a potential imaging biomarker for adolescent-onset schizophrenia: A resting-state fMRI study and support vector machine analysis. ( 28587813 )
2018
24
The role of genetic liability in the association of urbanicity at birth and during upbringing with schizophrenia in Denmark. ( 28659227 )
2018
25
Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism. ( 29352035 )
2018
26
Integrating genome-wide association study and expression quantitative trait locus study identifies multiple genes and gene sets associated with schizophrenia. ( 29024729 )
2018
27
Associations between cognition and internalizing problems in young adults with early-onset schizophrenia: A 13-year follow-up study. ( 29709790 )
2018
28
Prevalence of childhood trauma and correlations between childhood trauma, suicidal ideation, and social support in patients with depression, bipolar disorder, and schizophrenia in southern China. ( 29223913 )
2018
29
Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence. ( 29594135 )
2018
30
Psychological Distress Among Caregivers of Individuals With a Diagnosis of Schizophrenia or Schizoaffective Disorder. ( 28967321 )
2018
31
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics. ( 29331603 )
2018
32
Psychosocial functioning in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 29316520 )
2018
33
TAR DNA-Binding Protein 43 and Disrupted in Schizophrenia 1 Coaggregation Disrupts Dendritic Local Translation and Mental Function in Frontotemporal Lobar Degeneration. ( 29752072 )
2018
34
Endogenous Cell Type-Specific Disrupted in Schizophrenia 1 Interactomes Reveal Protein Networks Associated With Neurodevelopmental Disorders. ( 29961565 )
2018
35
Reduced Functional Brain Activation and Connectivity During a Working Memory Task in Childhood-Onset Schizophrenia. ( 29496125 )
2018
36
Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: A meta-analysis. ( 29410289 )
2018
37
Brain functional and perfusional alterations in schizophrenia: an arterial spin labeling study. ( 29229240 )
2018
38
GnRH Antagonist and Antipsychotic Medication for Pedophilia Comorbid with Schizophrenia and Intellectual Disability. ( 29938360 )
2018
39
Do clinical characteristics predict the cognitive course in early-onset schizophrenia-spectrum disorders? ( 29573345 )
2018
40
Zotepine-induced convulsion at a low dose in a case of paranoid schizophrenia. ( 29363876 )
2018
41
Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia. ( 29302076 )
2018
42
Inhibition of STEP<sub>61</sub>ameliorates deficits in mouse and hiPSC-based schizophrenia models. ( 27752082 )
2018
43
A complex network approach reveals a pivotal substructure of genes linked to schizophrenia. ( 29304112 )
2018
44
The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjects. ( 29201642 )
2018
45
The GABRB3 Polymorphism and its Association with Schizophrenia. ( 29196882 )
2018
46
Multisite generalizability of schizophrenia diagnosis classification based on functional brain connectivity. ( 28601499 )
2018
47
Is the serious ambient air pollution associated with increased admissions for schizophrenia? ( 29980080 )
2018
48
Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress. ( 29064136 )
2018
49
GluD1, linked to schizophrenia, controls the burst firing of dopamine neurons. ( 28696429 )
2018
50
Decreased value-sensitivity in schizophrenia. ( 29096335 )
2018

Variations for Schizophrenia

UniProtKB/Swiss-Prot genetic disease variations for Schizophrenia:

75
# Symbol AA change Variation ID SNP ID
1 RTN4R p.Arg119Trp VAR_079154 rs74315508
2 RTN4R p.Arg196His VAR_079155 rs74315509
3 RTN4R p.Arg292His VAR_079231
4 RTN4R p.Arg377Gln VAR_079235 rs779384862
5 RTN4R p.Arg377Trp VAR_079236 rs748655075

ClinVar genetic disease variations for Schizophrenia:

6
(show all 25)
# Gene Variation Type Significance SNP ID Assembly Location
1 MTHFR NM_005957.4(MTHFR): c.1286A> C (p.Glu429Ala) single nucleotide variant drug response rs1801131 GRCh37 Chromosome 1, 11854476: 11854476
2 MTHFR NM_005957.4(MTHFR): c.1286A> C (p.Glu429Ala) single nucleotide variant drug response rs1801131 GRCh38 Chromosome 1, 11794419: 11794419
3 RTN4R NM_023004.5(RTN4R): c.355C> T (p.Arg119Trp) single nucleotide variant risk factor rs74315508 GRCh37 Chromosome 22, 20230301: 20230301
4 RTN4R NM_023004.5(RTN4R): c.355C> T (p.Arg119Trp) single nucleotide variant risk factor rs74315508 GRCh38 Chromosome 22, 20242778: 20242778
5 RTN4R NM_023004.5(RTN4R): c.587G> A (p.Arg196His) single nucleotide variant risk factor rs74315509 GRCh37 Chromosome 22, 20230069: 20230069
6 RTN4R NM_023004.5(RTN4R): c.587G> A (p.Arg196His) single nucleotide variant risk factor rs74315509 GRCh38 Chromosome 22, 20242546: 20242546
7 HTR2A HTR2A, 102T-C single nucleotide variant risk factor
8 MC4R NM_005912.2(MC4R): c.105C> A (p.Tyr35Ter) single nucleotide variant Pathogenic rs13447324 GRCh37 Chromosome 18, 58039478: 58039478
9 MC4R NM_005912.2(MC4R): c.105C> A (p.Tyr35Ter) single nucleotide variant Pathogenic rs13447324 GRCh38 Chromosome 18, 60372245: 60372245
10 COMT NM_000754.3(COMT): c.214G> T (p.Ala72Ser) single nucleotide variant risk factor rs6267 GRCh37 Chromosome 22, 19950263: 19950263
11 COMT NM_000754.3(COMT): c.214G> T (p.Ala72Ser) single nucleotide variant risk factor rs6267 GRCh38 Chromosome 22, 19962740: 19962740
12 ABCA13 NM_152701.4(ABCA13): c.11473+2T> C single nucleotide variant Likely pathogenic rs797045205 GRCh37 Chromosome 7, 48427558: 48427558
13 ABCA13 NM_152701.4(ABCA13): c.11473+2T> C single nucleotide variant Likely pathogenic rs797045205 GRCh38 Chromosome 7, 48387961: 48387961
14 SETD1A NM_014712.2(SETD1A): c.518-2A> G single nucleotide variant Pathogenic rs869312829 GRCh37 Chromosome 16, 30974752: 30974752
15 SETD1A NM_014712.2(SETD1A): c.518-2A> G single nucleotide variant Pathogenic rs869312829 GRCh38 Chromosome 16, 30963431: 30963431
16 SETD1A NM_014712.2(SETD1A): c.1272delC (p.Tyr425Thrfs) deletion Pathogenic rs869312830 GRCh37 Chromosome 16, 30976335: 30976335
17 SETD1A